Evidence mapPaperPMID 39072050Full record

SynthesisJournal of diabetes research2024

Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.

Sanbao Chai, Yapin Niu, Fengqi Liu, Shanshan Wu, Zhirong Yang, Feng Sun

Abstract readComparative StudySystematic Review
In one paragraph

Synthesis in Journal of diabetes research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sanbao ChaiDepartment of Endocrinology and Metabolism Peking University International Hospital, Beijing 102206, China.ORCID https://orcid.org/0000-0002-8746-518X
Yapin NiuDepartment of Epidemiology and Biostatistics Peking University School of Public Health, Beijing 100083, China.ORCID https://orcid.org/0009-0000-5732-2682
Fengqi LiuDepartment of Epidemiology and Biostatistics Peking University School of Public Health, Beijing 100083, China.ORCID https://orcid.org/0000-0002-6055-529X
Shanshan WuNational Clinical Research Center of Digestive Diseases Capital Medical University Affiliated Beijing Friendship Hospital, Beijing 100050, China.ORCID https://orcid.org/0000-0001-9791-8093
Zhirong YangShenzhen Institute of Advanced Technology Chinese Academy of Sciences, Shenzhen 518055, China.ORCID https://orcid.org/0000-0002-1562-0603
Feng SunDepartment of Epidemiology and Biostatistics Peking University School of Public Health, Beijing 100083, China.ORCID https://orcid.org/0000-0003-4334-6805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 InhibitorsAdministration, OralBlood GlucoseGlycated HemoglobinHumansTreatment OutcomeBlood GlucoseDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 Inhibitorsbasic insulinDPP-4GLP-1SGLT-2Type 2 diabetesumbrella review

Identifiers

PMID39072050
PMCPMC11283333

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.